25437-95-0

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure allows it to be a building block for the development of new pharmaceuticals with potential therapeutic applications.
Used in Organic Synthesis:
Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester is also used as a building block in the synthesis of other organic compounds. Its versatile structure makes it a valuable component in the creation of new chemical entities for various applications.

Upstream product

• 25437-94-9 ethyl 4-(4-hydroxypiperidin-1-yl)benzoate 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 79421-38-8 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzoic acid ethyl ester 

Downstream Products

• 926933-68-8 4-(4-biphenyl-4-ylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester 
• 926933-67-7 4-(4-biphenyl-2-ylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester 
• 926933-56-4 4-(4-isobutyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester 
• 926933-58-6 4-(4-n-butyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester 
• 406233-70-3 ethyl 4-(4-methylenepiperidin-1-yl)benzoate 
• 926934-14-7 4-[4-(4-fluoro-benzylidene)-piperidin-1-yl]-benzoic acid ethyl ester 
• 926933-57-5 4-[4-(2,2-dimethyl-propyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 926933-59-7 4-(4-cyclohexylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester 
• 926933-62-2 4-[4-(3-chlorobenzyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 926933-64-4 4-[4-(2-methylbenzyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 926933-66-6 4-[4-(2-bromobenzyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 926933-65-5 4-[4-(2-methoxybenzyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 870812-22-9 4-[4-(2-fluorobenzyl)-4-hydroxy-piperidin-1-yl]-benzoic acid ethyl ester 
• 926933-93-9 ethyl 4-(2-methyl-3-oxo-1-oxa-4,8-diazaspiro[4.5]decan-8-yl)benzoate 

Relevant academic research and scientific papers

Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF

Peptidoglycan is an essential component of the bacterial cell wall, and enzymes involved in its biosynthesis represent validated targets for antibacterial drug discovery. MurF catalyzes the final intracellular peptidoglycan biosynthesis step: the addition of D-Ala-D-Ala to the nucleotide precursor UDP-MurNAc-L-Ala-γ-D-Glu-meso-DAP (or L-Lys). As MurF has no human counterpart, it represents an attractive target for the development of new antibacterial drugs. Using recently published cyanothiophene inhibitors of MurF from Streptococcus pneumoniae as a starting point, we designed and synthesized a series of structurally related derivatives and investigated their inhibition of MurF enzymes from different bacterial species. Systematic structural modifications of the parent compounds resulted in a series of nanomolar inhibitors of MurF from S. pneumoniae and micromolar inhibitors of MurF from Escherichia coli and Staphylococcus aureus. Some of the inhibitors also show antibacterial activity against S. pneumoniae R6. These findings, together with two new co-crystal structures, represent an excellent starting point for further optimization toward effective novel antibacterials.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS

Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds,

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

BCL-2 INHIBITORS

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer.

HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

N-acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.

N-Acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula Are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.

2-Arylbenzo(b)(1,6)naphthyridines as inhibitors of interleukin 1

There is disclosed a method for the treatment of inflammatory conditions and of collegenase-induced tissue destruction which comprises the administration of a therapeutically effective amount of a compound of the formula STR1 wherein R1 is phen

Pyrazolo(4,3-c)quinolines

There are disclosed compounds of the formula STR1 wherein the various substituents are defined hereinbelow, and, by virtue of their ability to inhibit interleukin 1, their use as antiinflammatory agents and in treatment of disease states involving enzymat